Wnt2 as a new therapeutic target in malignant pleural mesothelioma
Julien Mazières(Université Toulouse III - Paul Sabatier), David M. Jablons(City College of San Francisco)
Cited by 69
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k